Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Glioblastoma multiforme Clinical Trials

A listing of Glioblastoma multiforme medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (54) clinical trials

People with Glioblastoma are asked to participate in a research study being conducted by Northshore University Hospital.

Phase N/A

Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis

This study is being done to learn about a new drug, Ceritinib (LKD378). The results of the study may reveal how the drug works for cancer that spreads to the brain (metastases) and for a type of brain cancer called glioblastoma (GBM). Subjects are persons scheduled to have surgery to ...

Phase N/A

Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma

PRIMARY OBJECTIVES: I. Measurement of tissue concentration of ixazomib (ixazomib citrate) in a glioblastoma after preoperative administration. II. Measurement of blood and plasma concentration of ixazomib during surgical sampling after preoperative administration. SECONDARY OBJECTIVES: I. Assessment of the safety of ixazomib after single dose administration in glioblastoma patients undergoing surgery ...

Phase N/A

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

900 mg/d is the maximally tolerated dose (MTD), as determined in a recent Novartis-sponsored Phase I study for advanced solid tumor patients. The recommended dose expansion and Phase 2 is 600mg/d for 3 weeks on and 1 week off. Due to drug pharmacokinetics, the MTD (900mg) dose will be used ...

Phase N/A

Tryptophan Metabolism in Human Brain Tumors

If you agree to take part in this research study, you will be asked to have: A PET scan, 2. brief clinical questionnaires, and 3. biochemical studies of blood and tumor tissue. You will also have a second PET scan later, 2-3 months after the start of NovoTTF therapy, to ...

Phase N/A

A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM)

This feasibility study will assess the effects of the Nativis Voyager therapy in patients with first or second recurrence of GBM who have either failed standard of care or are intolerant to therapy. The study will enroll and treat up to 32 subjects with Voyager plus lomustine (CCNU). Safety and ...

Phase N/A

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

BACKGROUND Preliminary data generated from our pilot protocol 02-C-0064 suggests that the urinary VEGF and MMP level at the one month follow-up time point compared to the last on-treatment time point collection may be predictive of tumor recurrence at one year (l). Note that this preliminary study included patients with ...

Phase N/A

Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma

Investigators will compare the novel to the standard DSC-PWI methods in twenty five GBM patients to determine whether novel method improves image quality in tumor regions. We will also compare accuracy of pseudoprogression (PsP) vs. early progressive disease (ePD) determinations by the two techniques. If successful, the project will culminate ...

Phase N/A

Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma

PRIMARY OBJECTIVES: I. To improve the visualization/delineation of glioblastoma lesions using delayed 18F-FDG PET/CT imaging. OUTLINE Patients receive fludeoxyglucose F-18 intravenously (IV). Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection. Note Standard Uptake Value (SUV) is ...

Phase N/A

Determination of Immune Phenotype in Glioblastoma Patients

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Despite intensive research efforts and a multimodal management that actually consists of surgery, radiotherapy and chemotherapy with temozolomide, the prognosis is dismal. The aim of the current observational study is to determine immune phenotypes in individual patients with ...

Phase N/A